Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: Overall survival data from the phase IIb LUX-Lung 7 trial

Annals of Oncology

Volumn 28, Issue 2, 2017, Pages 270-277

  Paz Ares, Luis ^a   Tan, E H ^b   O'Byrne, K ^c   Zhang, L ^d   Hirsh, V ^e   Boyer, M ^f   Yang, J C H ^g   Mok, T ^h   Lee, K H ⁱ   Lu, S ^j   Shi, Y ^k   Lee, D H ^l   Laskin, J ^m   Kim, D W ⁿ   Laurie, S A ^o   Kolbeck K ^p   Fan, J ^q   Dodd, N ^r   Marten A ^s   Park, K ^t  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^c QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^d SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^e MCGILL UNIVERSITY   (Canada)

^f Chris O'Brien Lifehouse ^*  (Australia)

^g NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^h CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

ⁱ Chungbuk National University Hospital   (South Korea)

^j SHANGHAI JIAO TONG UNIVERSITY   (China)

^k PEKING UNION MEDICAL COLLEGE   (China)

^l Asan Medical Center   (South Korea)

^m BRITISH COLUMBIA CANCER AGENCY   (Canada)

ⁿ Seoul National University Hospital   (South Korea)

^o OTTAWA REGIONAL CANCER CENTRE   (Canada)

^p KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^q BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^r BOEHRINGER INGELHEIM LTD   (United Kingdom)

^s BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^t Sungkyunkwan University School of Medicine   (South Korea)

more..

Author keywords

Afatinib; Gefitinib; NSCLC; Overall survival

Indexed keywords

AFATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; OLMUTINIB; OSIMERTINIB; POZIOTINIB; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; QUINAZOLINE DERIVATIVE;

ACNE; ADULT; ARTICLE; BRAIN METASTASIS; CANCER STAGING; DIARRHEA; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EGFR GENE; EXON; FATIGUE; FOLLOW UP; GENE DELETION; GENE MUTATION; HUMAN; HYPERTRANSAMINASEMIA; INTERSTITIAL LUNG DISEASE; KIDNEY FAILURE; LIVER FAILURE; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; TREATMENT RESPONSE; AGED; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GENETICS; KAPLAN MEIER METHOD; LUNG TUMOR; MALE; MIDDLE AGED; MORTALITY; MUTATION; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROPORTIONAL HAZARDS MODELS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 85015712569     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw611     Document Type: Article

References (26)

1. Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380-2388.
2. Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11: 121-128.
3. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-957.
4. Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13: 239-246.
5. Sequist LV, Yang JC, Yamamoto N et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013; 31: 3327-3334.
6. Wu YL, Zhou C, Hu CP et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 2014; 15: 213-222.
7. Wu YL, Zhou C, Liam CK et al. First-line erlotinib versus gemcitabine/ cisplatin in patients with advanced EGFR mutation-positive non-smallcell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Ann Oncol 2015; 26: 1883-1889.
8. Zhou C, Wu YL, Chen G et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive nonsmall-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, openlabel, randomised, phase 3 study. Lancet Oncol 2011; 12: 735-742.
9. Park K, Tan EH, O'Byrne K et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol 2016; 17: 577-589.
10. Yang JC, Wu YL, Schuler M et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 2015; 16: 141-151.
11. Zhou C, Wu YL, Chen G et al. Final overall survival results from a randomised, Phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802). Ann Oncol 2015; 26: 1877-1883.
12. Fukuoka M, Wu YL, Thongprasert S et al. Biomarker analyses and final overall survival results from a phase III, randomized, openlabel, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011; 29: 2866-2874.
13. Inoue A, Kobayashi K, Maemondo M et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol 2013; 24: 54-59.
14. Yoshioka H, Mitsudomi T, Morita S et al. Final overall survival results of WJTOG 3405, a randomized phase 3 trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer (NSCLC) harboring mutations of the epidermal growth factor receptor (EGFR). J Clin Oncol 2014; 32 (Suppl. 15): abstract 8117.
15. Lee CK, Wu YL, Ding PN et al. Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis. J Clin Oncol 2015; 33: 1958-1965.
16. Inoue A, Kobayashi K, Maemondo M et al. Final overall survival results of NEJ002, a phase III trial comparing gefitinib to carboplatin (CBDCA) plus paclitaxel (TXL) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutations. J Clin Oncol 2011; 29 (Suppl. 15): abstract 7519.
17. Miller VA, Hirsh V, Cadranel J et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUXLung 1): a phase 2b/3 randomised trial. Lancet Oncol 2012; 13: 528-538.
18. Schuler M, Yang JC, Park K et al. Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. Ann Oncol 2016; 27: 417-423.
19. Cappuzzo F, Morabito A, Normanno N et al. Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer. Lung Cancer 2016; 99: 31-37.
20. Pilz LR, Manegold C, Schmid-Bindert G. Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer? Transl Lung Cancer Res 2012; 1: 26-35.
21. Janne PA, Yang JC, Kim DW et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 2015; 372: 1689-1699.
22. Park K, Lee JS, Lee KH et al. Updated safety and efficacy results from phase I/II study of HM61713 in patients (pts) with EGFR mutation positive non-small cell lung cancer (NSCLC) who failed previous EGFRtyrosine kinase inhibitor (TKI). J Clin Oncol 2015; 33 (Suppl. 15): abstract 8084.
23. Kobayashi S, Boggon TJ, Dayaram T et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005; 352: 786-792.
24. Pao W, Miller VA, Politi KA et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2: e73.
25. Wu SG, Liu YN, Tsai MF et al. The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients. Oncotarget 2016; 7: 12404-12413.
26. Yang J-J, Zhou Q, Yan H-H et al. A Randomized Controlled Trial of Erlotinib versus Gefitinib in Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations (CTONG0901). J Thorac Oncol 2015; 10 (Suppl 2): S321.